Clinica Chimica Acta：经皮冠状动脉介入治疗急性ST段抬高性心肌梗死患者术前纤维蛋白原-白蛋白比值对死亡率的影响

2019-08-06 不详 MedSci原创

研究了基于炎症和血液流变学改变的急性<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:"Calibri","sans-serif"; mso-fareast-font-family:宋体;mso-bidi-font-family:"Ti

研究了基于炎症和血液流变学改变的急性ST段抬高心肌梗死（STEMI）患者的纤维蛋白原 - 白蛋白比值（FAR）的预后价值，并确定FAR是否可以作为预测急性冠状动脉事件信息的全球注册(GRACE)评分的补充增量预测信息。

研究人员回顾性分析了475例接受pPCI治疗的STEMI患者。采用Kaplan-Meier曲线、Cox比例危险回归模型、Hosmer-Lemeshow检验评价FAR对患者的预后价值。

根据0.080的最佳截断值，将患者分为高FAR组(≥0.080)和低FAR组(<0.080)。研究结果显示，总共有59名患者（12.4％）死亡; 高FAR患者的死亡率高于低FAR患者（20.5％vs。8.6％，p <.001）。 FAR与C反应蛋白，GRACE评分和Gensini评分呈正相关（p <.001）。在多变量分析中，FAR是接受pPCI的STEMI患者的独立预后因素。

研究表明，术前FAR是进行pPCI的STEMI患者的一个独立预后因素，可能改善STEMI的风险分层。

原始出处：

LeiXiao，YuJia，The impact of preoperative fibrinogen-albumin ratio on mortality in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2020-04-04 axin009

#纤维蛋白#

23 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-12-30 3631181

#冠状动脉介入治疗#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-08-11 windight

#CTA#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-08-08 珙桐

#白蛋白#

20 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-08-08 aids213

#经皮冠状动脉介入治疗#

36 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-08-08 waiwai3030

#纤维蛋白原#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-08-08 gdsun

#ST段抬高#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1997277, encodeId=7c54199e2771a, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sat Apr 04 07:22:00 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648952, encodeId=2a4b1648952d4, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Dec 30 19:22:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849663, encodeId=9a7918496638a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 11 10:22:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304658, encodeId=d6d613046589f, content=<a href='/topic/show?id=cd37e1767b5' target=_blank style='color:#2F92EE;'>#白蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71767, encryptionId=cd37e1767b5, topicName=白蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320762, encodeId=02bc1320e626d, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362617, encodeId=c93c136261ef2, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423090, encodeId=8c051423090f0, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624417, encodeId=9a84162441ec3, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Thu Aug 08 05:22:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
2019-08-08 hyf035

#ST段#

21 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

急重症科

Clinica Chimica Acta：经皮冠状动脉介入治疗急性ST段抬高性心肌梗死患者术前纤维蛋白原-白蛋白比值对死亡率的影响

相关资讯

科室

工具

服务